XOMA Corporation (NASDAQ:XOMA) and Novo Nordisk to Work Together for XMetA Program in Diabetes

1053

XOMA Corporation (NASDAQ:XOMA), the leading company in the development and discovery of therapeutic antibodies is to work together with Novo Nordisk for the XMetA program in diabetes. Xoma has announced that it has given an exclusive license to Novo Nordisk A/S authorizing the latter with global development and commercialization rights of the XMetA program. The program is dedicated to allosteric monoclonal antibodies that up-regulate the insulin receptor.

Terms of Agreement

The terms of the agreement give XOMA the right to retain the commercialization of rare disease indications. However, Novo Nordisk also has an option to add these rights to its license. Nova Nordisk will pay $5.0 million to XOMA in the form of an upfront payment. The agreement also includes potential additional development, commercial milestones and regulatory payment of around $290.0 million. Moreover, XOMA will also receive the tiered royalties on the sale of the products.

 Nova Nordisk Can Further Develop XOMA’s Activators

According to the Chief Operating Officer and Senior Vice-President at XOMA, Jim Neal, Novo Nordisk, being the leader in the development of therapies used for treating diabetes mellitus can further develop his company’s first-in-class insulin receptor activators. The scientists of XOMA have discovered these activators.

He further said that the strategy of the company is to come up with new therapeutics for the various endocrine diseases, especially those belonging to rare categories. XOMA has been successful in structuring an agreement with Novo Nordisk that allows it to retain the commercialization rights.

XOMA Scientists Identify Novel Method to Treat Type 2 Diabetes

The scientists of XOMA studied the insulin receptor and have successfully come up with the novel method of treating the type 2 diabetes mellitus. This discovery stimulated the development of XMetA program that includes a series of fully human, novel, allosteric monoclonal, high-affinity antibodies with the ability to restrain the insulin receptor partially. In the past few years, the XOMA scientists have made a great progress to unravel the pharmacology of the compounds involved in the program.

According to Paul Rubin, M.D., Research, Development, Chief Medical Officer, and Senior Vice President at XOMA Corporation (NASDAQ:XOMA), the Vitro data has revealed that the program mimics the glucose regulatory functions of the insulin, excluding its mitogenic actions.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.